<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02493764</url>
  </required_header>
  <id_info>
    <org_study_id>7655A-014</org_study_id>
    <secondary_id>2015-000246-34</secondary_id>
    <secondary_id>163240</secondary_id>
    <nct_id>NCT02493764</nct_id>
  </id_info>
  <brief_title>Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)</brief_title>
  <acronym>RESTORE-IMI 2</acronym>
  <official_title>A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare treatment with imipenem/relebactam/cilastatin (IMI/REL) as a
      fixed-dose combination (FDC) with piperacillin/tazobactam (PIP/TAZ) FDC in participants with
      hospital-acquired and ventilator-associated bacterial pneumonia. The primary hypothesis is
      that IMI/REL is non-inferior to PIP/TAZ in the incidence rate of all-cause mortality.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2015</start_date>
  <completion_date type="Anticipated">May 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants surviving at Day 28</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a favorable clinical response at early follow up visit</measure>
    <time_frame>Up to 16 days after end of therapy (up to Day 30)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">536</enrollment>
  <condition>Bacterial Pneumonia</condition>
  <arm_group>
    <arm_group_label>IMI/REL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imipenem 500 mg + relebactam 250 mg + cilastatin 500 mg as a FDC administered intravenously (IV) every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PIP/TAZ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Piperacillin 4000 mg + tazobactam 500 mg as a FDC administered IV every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem</intervention_name>
    <description>Imipenem 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days</description>
    <arm_group_label>IMI/REL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relebactam</intervention_name>
    <description>Relebactam 250 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days</description>
    <arm_group_label>IMI/REL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilastatin</intervention_name>
    <description>Cilastatin 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days</description>
    <arm_group_label>IMI/REL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin</intervention_name>
    <description>Piperacillin 4000 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days</description>
    <arm_group_label>PIP/TAZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazobactam</intervention_name>
    <description>Tazobactam 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days</description>
    <arm_group_label>PIP/TAZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <description>Linezolid 600 mg administered open-label by IV every 12 hours for up to 14 days</description>
    <arm_group_label>IMI/REL</arm_group_label>
    <arm_group_label>PIP/TAZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Requires treatment with IV antibiotic therapy for hospital-acquired bacterial
             pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP)

          -  Fulfills clinical and radiographic criteria, with onset of criteria occurring after
             more than 48 hour of hospitalization or within 7 days after discharge from a hospital
             (for HABP); or at least 48 hours after mechanical ventilation (for VABP)

          -  Has an adequate baseline lower respiratory tract specimen obtained for Gram stain and
             culture

          -  Has an infection known or thought to be caused by microorganisms susceptible to the IV
             study therapy

          -  Agrees to allow any bacterial isolates obtained from protocol-required specimens
             related to the current infection to be provided to the Central Microbiology Reference
             Laboratory for study-related microbiological testing, long term storage, and other
             future testing

          -  Is not of reproductive potential; or if of reproductive potential agrees to avoid
             impregnating a partner or avoid becoming pregnant, by practicing abstinence or using
             acceptable contraception

        Exclusion Criteria:

          -  Has a baseline lower respiratory tract specimen Gram stain that shows the presence of
             Gram-positive cocci only

          -  Has confirmed or suspected community-acquired bacterial pneumonia (CABP)

          -  Has confirmed or suspected pneumonia of viral, fungal or parasitic origin

          -  Has HABP/VABP caused by an obstructive process, including lung cancer or other known
             obstruction

          -  Has a carcinoid tumor or carcinoid syndrome

          -  Has active immunosuppression defined as either receiving immunosuppressive medications
             or having a medical condition associated with immunodeficiency

          -  Is expected to survive for less than 72 hours

          -  Has a concurrent condition or infection that would preclude evaluation of therapeutic
             response

          -  Has received effective antibacterial drug therapy for the index infection of HABP/VABP
             for more than 24 hours continuously, during the previous 72 hours

          -  Has a history of serious allergy, hypersensitivity or a serious reaction to any
             penicillin or beta-lactamase inhibitors

          -  Female is pregnant, expecting to conceive, is breastfeeding or plans to breastfeed

          -  Has a history of seizure disorder requiring ongoing prior treatment with
             anti-convulsive therapy within the last 3 years

          -  Anticipates treatment with the following: valproic acid or divalproex sodium,
             serotonin re-uptake inhibitors, tricyclic antidepressants, or serotonin receptor
             antagonists, meperidine, buspirone, concomitant systemic antibacterial agents,
             antifungal or antiviral therapy for the index infection of HABP/VABP

          -  Is currently undergoing hemodialysis or peritoneal dialysis

          -  Is currently participating in, has participated in during the previous 30 days, or
             anticipates to participate in any other clinical study involving the administration of
             experimental medication

          -  Has previously participated in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0514)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0546)</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0512)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0504)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0518)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0522)</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0524)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0549)</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0537)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0529)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0525)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Beatriz Trillo</last_name>
      <phone>54 11 6090 7336</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Brasil</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MSD Online</last_name>
      <phone>0800 012 22 32</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Bulgaria EOOD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florina Prundaru</last_name>
      <phone>40212333530</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Canada</name>
      <address>
        <city>Kirkland</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Information Centre Centre d'information medicale Merck Canada Inc.</last_name>
      <phone>514-428-8600 / 1-800-567-2594</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MDS Colombia SAS</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liliana Ferro</last_name>
      <phone>57 12191093</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme d.o.o</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Szabolcs Barotfi</last_name>
      <phone>36 1 888 5300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme OU</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>460857813500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD France</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Bouchara</last_name>
      <phone>33 180464417</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Sharp &amp; Dohme GmbH</name>
      <address>
        <city>Haar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>German Medical Information Center</last_name>
      <phone>49 800 673 673 673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD CARD</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgar R Hernandez</last_name>
      <phone>502 24979595</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Italia S.r.l.</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Chiaretta Fattore</last_name>
      <phone>39 0636191739</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD K.K.</name>
      <address>
        <city>Chiyoda-Ku, Tokyo</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Japan Call Center</last_name>
      <phone>81-3-6272-1957</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Korea LTD</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TaeYoun Jo</last_name>
      <phone>8223312313</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Latvija SIA</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>460857813500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UAB &quot;Merck Sharp &amp; Dohme&quot;</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>460857813500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Barajas</last_name>
      <phone>52 5554819650</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Norge A/S</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>46857813545</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme, Peru S.R.L.</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodolfo Lozano</last_name>
      <phone>5114115910</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme (I.A.) Corporation</name>
      <address>
        <city>Makati</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgina Arnold</last_name>
      <phone>61289888212</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Lda.</name>
      <address>
        <city>Paco D'arcos</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lourdes Lopez-Bravo</last_name>
      <phone>(0034) 913210654</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme IDEA, Inc.</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Serebriakova</last_name>
      <phone>74959167100, EXT.366</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Szabolcs Barotfi</last_name>
      <phone>36 1 888 5300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp and Dohme de Espana S.A.</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lourdes Lopez-Bravo</last_name>
      <phone>(0034) 913210654</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Ilaclari Ltd. Sti</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betul Erdogan</last_name>
      <phone>2123361232</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Ukraine LLC</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serhiy Mykhaylov</last_name>
      <phone>38 050 3107198</phone>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Romania</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2015</study_first_submitted>
  <study_first_submitted_qc>July 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2015</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>MK-7655</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

